

## Priority Eligibility Criteria and Prescribing for Molnupiravir

Prescribers **must comply** with requirements of the US Food and Drug Administration's [Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir](#) and with the State of Michigan Priority Eligibility Criteria for this medication. Patients must have tested positive for SARS-CoV-2.

Molnupiravir is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults (18 years of age), and

- with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and
- who are at high risk for progression to severe COVID-19, including hospitalization or death, and
- for whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate, and
- who meet the current [Priority Eligibility Criteria \(see Page 6\)](#)

### Dosing and Administration of Molnupiravir (see full Fact Sheet for Healthcare Providers)

- 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days, with or without food.
- Take molnupiravir as soon as possible after a diagnosis of COVID19 has been made, and within 5 days of symptom onset.
- Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2.
- Molnupiravir is not authorized for use for longer than 5 consecutive days because the safety and efficacy have not been established.

### Dosage Forms of Molnupiravir

- Capsules: 200 mg

### Warning and Precautions for Molnupiravir

- Use in Pregnancy /Embryo-Fetal Toxicity: **Molnupiravir is not recommended for use during pregnancy.**
- Bone and Cartilage Toxicity: Molnupiravir is not authorized for use in patients less than 18 years of age because it may affect bone and cartilage growth.

### Contraindications for Molnupiravir

- No contraindications have been identified based on the limited available data on the emergency use of molnupiravir authorized under this EUA.
- **Not to be used in pregnancy**

### Medication Interactions with Molnupiravir

No drug interactions have been identified based on the limited available data on the emergency use of molnupiravir authorized under this EUA.